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http://dx.doi.org/10.1016/j.ccell.2014.09.019SUMMARYGenetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor tyrosine kinase,
as a tractable molecular target in neuroblastoma. We describe comprehensive genomic, biochemical, and
computational analyses of ALK mutations across 1,596 diagnostic neuroblastoma samples. ALK tyrosine
kinase domain mutations occurred in 8% of samples—at three hot spots and 13 minor sites—and correlated
significantly with poorer survival in high- and intermediate-risk neuroblastoma. Biochemical and computa-
tional studies distinguished oncogenic (constitutively activating) from nononcogenic mutations and allowed
robust computational prediction of their effects. The mutated variants also showed differential in vitro crizo-
tinib sensitivities. Our studies identify ALK genomic status as a clinically important therapeutic stratification
tool in neuroblastoma and will allow tailoring of ALK-targeted therapy to specific mutations.INTRODUCTION
Neuroblastomas are embryonal tumors that arise from the sym-
pathetic nervous system and represent themost frequently diag-
nosedmalignancy in the first year of life (Cheung and Dyer, 2013;
Maris, 2010). Despite improvements in treatment over recent de-
cades, the cure rates for patients with high-risk neuroblastoma
(Maris, 2010) lag significantly behind those of other commonSignificance
This work establishes a preclinical rationale for the therapeuti
therapy based on ALK genomic status. Beyond previously e
(mutation or amplification) is a prognostic biomarker for poor
mutation also correlates with a worse prognosis in high- and in
analyses allowed us to determine which mutations are oncoge
for identifying disease-significantALKmutations as they emerg
suggests strategies for its application in the clinic. Stratification
the outcomes for a significant patient subset.
682 Cancer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Incchildhood cancers (Smith et al., 2010). Current treatments rely
on dose-intensive chemotherapy, radiation therapy, and immu-
notherapeutic targeting of the disialoganglioside GD2 (Maris,
2010; Yu et al., 2010). The most recent clinical studies of neuro-
blastoma have focused on escalating the dose intensity in both
induction and consolidation therapies, with evidence that this
improves the outcome (Pearson et al., 2008). The potential
long-term adverse effects of increasing treatment intensity onc stratification of neuroblastoma patients for ALK inhibition
stablished risk factors, the presence of an ALK aberration
er survival. The presence of an ALK tyrosine kinase domain
termediate-risk patients. Biochemical and functional cellular
nic drivers and to develop robust computational approaches
e clinically. Assessing the in vitro sensitivity to crizotinib also
based on ALK status has significant potential for improving
.
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et al., 2008; Smith et al., 2010), making it imperative that more
effective treatment strategies are developed.
One promising avenue for targeted therapy in neuroblastoma
focuses on anaplastic lymphoma kinase (ALK), a cell surface
neural receptor tyrosine kinase (RTK) expressed at significant
levels only in the developing embryonic and neonatal brain
(Iwahara et al., 1997; Morris et al., 1997). Germline mutations
in intact ALK have been identified recently as the major cause
of hereditary neuroblastoma (Mosse´ et al., 2008). These muta-
tions cause single amino acid missense substitutions in the
ALK tyrosine kinase domain (TKD) that promote constitutive,
ligand-independent activation of this RTK. Somatically acquired
ALK-activating mutations are also found as oncogenic drivers in
neuroblastoma (Chen et al., 2008; George et al., 2008; Hallberg
and Palmer, 2013; Janoueix-Lerosey et al., 2008; Mosse´ et al.,
2008). In addition, ALK gene amplification imparts an oncogenic
dependency in some cases (Janoueix-Lerosey et al., 2008;
Mosse´ et al., 2008). Therefore, ALK has emerged as a tractable
oncogene for targeted therapy in neuroblastoma. The same
tyrosine kinase is also found in oncogenic ALK fusion proteins
that arise from chromosomal translocations in, for example,
non-small-cell lung cancers (NSCLC) (Soda et al., 2007) and
anaplastic large-cell lymphomas (Morris et al., 1994), motivating
the development of small molecule ALK kinase inhibitors.
Dramatic response rates to crizotinib (an ALK/Met/Ros1 in-
hibitor) have been seen in pretreated patients with advanced
relapsed/refractory NSCLC harboring ALK rearrangements
(Kwak et al., 2010; Shaw and Engelman, 2013). These studies
validated ALK as a therapeutic target and led to the expedited
Food and Drug Administration approval of crizotinib for ALK-
translocated NSCLC.
The rapid clinical translation of findings with ALK in neuroblas-
toma prompted a phase 1 trial of crizotinib (NCT00939770) in pa-
tients with recurrent or refractory cancer. The results from this
trial highlighted the differential sensitivity to ALK kinase inhibition
of ALK-translocated versus ALK-mutated disease (Mosse´ et al.,
2013). The study also underlined the need for a further detailed
investigation of ALK mutations to optimize the clinical applica-
tion of ALK inhibitors in neuroblastoma. To achieve this goal, a
detailed analysis of the spectrum of ALKmutations, their clinical
significance in neuroblastoma, and their biochemical properties
is essential. The resulting data will underpin future approaches to
identifying patients likely to benefit from ALK inhibition in neuro-
blastoma and to predicting which newly emerging mutations are
clinically relevant.
RESULTS
To examine the spectrum of ALK mutations in neuroblastoma,
we analyzed germline and somatic ALK DNA alterations at diag-
nosis in samples from a cohort of 1,596 neuroblastoma patients
assembled in collaboration with the Children’s Oncology Group
(COG; Table 1).
ALK Mutations
Sequencing of ALK exons 21–28, encompassing the TKD-
encoding region, identified 126 diagnostic samples with at least
one mutation, corresponding to 8% of subjects (Table 1). Puta-Cantive disease-associated mutations were distributed throughout
the ALK TKD (Figure 1; Table S1 available online), with an addi-
tional mutation at R1060 (between the TKD and transmem-
brane domain). Three additional ALK TKD sequence variations
(R1231Q, I1250T, and D1349H) were observed that had been
listed previously in the National Center for Biotechnology Infor-
mation database of single nucleotide polymorphisms (dbSNP),
but with no known clinical significance or annotation in the
Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes
et al., 2011).
Three ‘‘hot spot’’ residues accounted for 85% of mutations
(Figure 1; Table 1): R1275 (43%), F1174 (30%), and F1245
(12%), consistent with previous studies (Chen et al., 2008;
George et al., 2008; Hallberg and Palmer, 2013; Janoueix-Lero-
sey et al., 2008; Mosse´ et al., 2008). R1275 was substituted with
glutamine or leucine in 3.4% of tumors (95% confidence interval
(CI): 2.5, 4.3%); F1174 was altered to L, I, V, C, or S in 2.4% of
tumors (95% CI: 1.6, 3.0%); and F1245 was changed to L, I, V,
or C in 0.9% of tumors (95% CI: 0.5, 1.4%). Two tumor samples
harbored mutations at I1170 (to N or S) and another two at I1171
(to N). Single incidences of substitution were seen at a further 15
positions, of which 7 represent mutations not found in current
databases (Table S1). Matched constitutional DNAwas available
for 88 of the 126 ALK-mutated samples and contained the
observed ALK substitution (indicating its presence in the germ-
line) in just 7 cases. Although no information about family history
is available, this is an expected rate based on previous analyses
(Knudson andStrong, 1972;Mosse´ et al., 2008). Twowere germ-
line R1275Q mutations, and the remaining five examples were
R1060H, I1183T, L1204F, R1231Q (also in dbSNP), and I1250T
(also in dbSNP) mutations (Table S1).
ALK mutations were found in 10.9% of MYCN-amplified tu-
mors versus 7.2% of those without MYCN amplification. Muta-
tions seen alongside MYCN amplification were biased toward
F1174 substitutions (41% in MYCN-amplified cases compared
with 30% overall). Further, MYCN amplification occurred in
39% of F1174-mutated tumors compared with an expected
overall frequency of 21% (p < 0.01). These data support previous
suggestions that F1174 mutations are overrepresented in
MYCN-amplified tumors but indicate a less skewed distribution
than reported earlier (De Brouwer et al., 2010). Consistent with
earlier results, however, patients with both amplified MYCN
and F1174-mutated ALK had a significantly worse event-free
survival (EFS, p < 0.0001) than patients with neither.
ALK Copy Number
Copy number variation at the ALK locus was observed in 17%
of cases for which it was measured (Table 1). Gain of the ALK lo-
cus (3–10 copies) was seen in 195 cases (15%), with high-level
amplification being more rare (24 samples) and whole gene
deletion rarer still (6 samples). The ALK gene is located 13.2
megabases centromeric of MYCN. ALK amplification occurred
concurrently withMYCN amplification in all but one case, consis-
tent with a previous report (Bagci et al., 2012). Accordingly,
because MYCN amplification identifies a patient as a member
of the high-risk group (Maris, 2010), ALK amplification occurred
exclusively in this group (Table S2) and was associated with an
inferior outcome (5-year overall survival [OS] of 23% versus
48% in high-risk patients without ALK amplification; p = 0.03;cer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc. 683
Table 1. Clinical, Genomic, and Survival Characteristics of the Overall Patient Cohort
Patient Cohort n (%) 5-Year EFSa ± SE (%) EFSa p Value 5-Year OSb ± SE (%) OSb p Value
Overall 1,596 67 ± 1.6 NA 75 ± 1.4 NA
Age
<18 months 756 (47) 81 ± 1.9 <0.0001 91 ± 1.4 <0.0001
R18 months 840 (53) 55 ± 2.3 62 ± 2.2
Risk Groupc
Low 626 (40) 87 ± 1.8 <0.0001d 97 ± 0.9 <0.0001d
Intermediate 292 (18) 85 ± 2.8 94 ± 1.9
High 664 (42) 40 ± 2.5 46 ± 2.6
Unknown 14
INSS Stage
Stage 1,2,3,4 s 927 (58) 83 ± 1.6 <0.0001 93 ± 1.1 <0.0001
Stage 4 661 (42) 44 ± 2.6 51 ± 2.6
Unknown 8
INPC Histology
Favorable 791 (54) 86 ± 1.6 <0.0001 96 ± 0.9 <0.0001
Unfavorable 683 (46) 49 ± 2.5 57 ± 2.5
Unknown 122
Ploidy
Hyperdiploid 998 (64) 73 ± 1.8 <0.0001 82 ± 1.6 <0.0001
Diploid 555 (36) 58 ± 2.9 65 ± 2.8
Unknown 43
MYCN Status
Not amplified 1,239 (78) 74 ± 1.6 <0.0001 83 ± 1.4 <0.0001
Amplified 340 (22) 39 ± 4.1 46 ± 4.2
Unknown 17
11q
No loss 636 (74) 77 ± 2.1 <0.0001 84 ± 1.8 <0.0001
LOH 219 (26) 59 ± 3.9 69 ± 3.6
Unknown 741
1p
No loss 696 (78) 77 ± 1.9 <0.0001 84 ± 1.7 <0.0001
LOH 198 (22) 52 ± 4.4 61 ± 4.3
Unknown 702
ALK Mutation
Present 126 (8) 53 ± 6.0 0.001 67 ± 5.9 0.02
Absent 1,458 (92) 68 ± 1.6 76 ± 1.5
Unknown 12
Site of ALK Mutation
F1174 38 (30) 51 ± 11.9 0.76 60 ± 12.7 0.32
F1245 15 (12) 46 ± 15.0 53 ± 14.8
R1275 54 (43) 54 ± 9.1 72 ± 8.5
Other mutation 19 (15) 63 ± 14.5 73 ± 13.4
ALK Copy Number
Amplified 24 (2) 24 ± 12.2 <0.0001 23 ± 11.7 <0.0001
Gain 195 (15) 47 ± 4.6 57 ± 4.6
No gain/not amplified 1,109 (83) 68 ± 1.9 77 ± 1.7
Loss 6 (<1) 40 ± 31.0 60 ± 26.8
Unknown status 262
(Continued on next page)
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Table 1. Continued
Patient Cohort n (%) 5-Year EFSa ± SE (%) EFSa p Value 5-Year OSb ± SE (%) OSb p Value
ALK Aberration
Mutation/amplification/gain/loss 335 (25) 47 ± 3.6 <0.0001 59 ± 3.6 <0.0001
None of the above 1,015 (75) 70 ± 2.0 78 ± 1.8
Unknown status 246
All tumor samples were derived from the initial diagnostic procedure.
aEvent-free survival.
bOverall survival.
cAs defined (Maris, 2010).
dLow/intermediate versus high risk.
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also had copy number data, ALK mutation and high-level gene
amplification were mutually exclusive (except for one G1286
variant). Further, 13% of ALK-mutated cases had low-level
gain of the ALK locus, similar to the percentage seen in the over-
all cohort. None demonstrated allelic deletion.
ALK Aberration and ALK Mutation Are Prognostic
Biomarkers of Inferior Survival
ALK mutations were observed in tumors from all clinical risk
groups and were more commonly observed in those from older
patients (Table S2). Across the whole cohort, the presence of
an ALK aberration (mutation or amplification) correlated with
reduced EFS and OS (Figures 2A and 2B), as did ALK mutation
(Table 1). The presence of any ALK aberration also correlated
with reduced EFS and OS in the high-risk group (Figures 2C
and 2D). In a univariable analysis, the presence of an ALKmuta-
tion was also correlated with reduced EFS in intermediate-risk
patients (Table S3), a heterogeneous group consisting mainly
of very young patients with metastatic disease or patients of
any age with large, unresectable primary tumors. The patient
outcome did not differ significantly according to the location of
the mutation in any analysis. Although robust biomarkers to
assign outcome probability have been characterized for patients
with low- and high-risk disease, themost appropriate therapy for
patients with intermediate-risk disease is less well defined, and
our findings suggest that ALK genetic status can be used to
identify cases within this group with the highest risk of treatment
failure.
In a multivariable analysis of the overall cohort, the presence
of an ALKmutation was found to have an independent influence
on survival, with a 1.4-fold greater risk of an event (or hazard
ratio, HR) within 5 years (95% CI: 1.1, 1.9) compared with cases
without an ALK mutation (Table 2). Similarly, an independent,
statistically significant correlation with outcome was seen in
three separate multivariable models (adjusted for other known
prognostic factors) for any ALK aberration (p = 0.0006; HR =
1.4; 95% CI: 1.2, 1.7), for ALK copy number gain (p = 0.04;
HR = 1.3; 95% CI: 1.0, 1.6), and for ALK amplification (p =
0.003; HR = 2.2; 95% CI: 1.3, 3.6).
In a multivariable model adjusted for the histologic category
(Table 2), the ALK mutation status showed a statistically signif-
icant correlation with reduced EFS in both the intermediate-
risk and high-risk patient groups, but not in the low-risk group,
again arguing for the utility of ALK mutation status in clinical
evaluation.CanPredicting Signaling Consequences of ALK TKD
Mutations
Our results establish that the presence of an ALK mutation
in neuroblastoma is associated with a more aggressive tumor
phenotype. Not all ALK substitutions observed in neuroblas-
toma patients are likely to be oncogenic drivers, however. It
will be important in refining therapeutic ALK mutation-based
patient stratification to predict, as they are observed, which
mutations are truly drivers that cause ligand-independent ALK
signaling and which are ‘‘passengers’’ or variants of unknown
significance. The current methods for predicting functional con-
sequences of patient-derived mutations fall short, especially for
activating mutations in kinases. Algorithms such as PolyPhen-2
(Adzhubei et al., 2010), SIFT (Kumar et al., 2009), and the
consensus classifier PredictSNP (Bendl et al., 2014) estimate
the likelihood of a given mutation having a deleterious effect
based on sequence conservation and other criteria. Poly-
Phen-2 or SIFT (or both) predict that every single ALK substitu-
tion listed in Table S1 adversely affects protein function (or is
‘‘damaging’’), except R1060H and R1231Q (a SNP). It seems
highly unlikely, given our understanding of kinases, that even
the ALK TKD C lobe mutations L1204F, T1343I, and D1349H
(also in dbSNP) are oncogenic. Moreover, the logic of conser-
vation-based algorithms is not appropriate for predicting gain-
of-function mutations in oncogenic kinase domains (Gnad
et al., 2013). Indeed, a recent analysis of more than 400 acti-
vating substitutions (Molina-Vila et al., 2014) revealed that
most driver mutations in oncogenic kinases do not occur at
conserved residues at all and that their accurate prediction
will require explicit attention to kinase regulation mechanisms.
Motivated by these considerations, we assessed the effects
of all ALK mutations defined here (Figure 1; Table S1) on
in vitro kinase activity to guide the development of better pre-
diction algorithms.
Biochemical Effects of Clinically Observed ALK TKD
Mutations
We first monitored the autophosphorylation of purified
mutated ALK TKDs using native gel electrophoresis (Figure S1)
as described previously (Bresler et al., 2011). The well studied
F1174L and R1275Q mutations greatly accelerated TKD auto-
phosphorylation as expected. So did substitutions at five of
the other positions listed in Table S1 (M1166, I1170, I1171,
F1245, and Y1278), as did the previously reported G1128A
and R1192P germline neuroblastoma mutations (Bourdeaut
et al., 2012; Janoueix-Lerosey et al., 2008; Mosse´ et al.,cer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc. 685
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Figure 1. Distribution of ALK Mutations
in Tumor Samples from Neuroblastoma
Patients
The 126 potentially disease-related mutations
observed were distributed over the 16 positions
marked in the ALK TKD plus R1060 (between the
TKD and the transmembrane domain, upper part
of the figure). Variants with red asterisks (in red
text) were also found in germline DNA. Mutations
not reported previously in neuroblastoma include
R1060H, I1170N, I1183T, L1204F, D1270G,
G1286R, and T1343I. See also Table S1 and
Figure S1.
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modest constitutive activation. By contrast, substitutions at
five other sites (I1183, A1200, R1231, T1343, and D1349)
and those found in dbSNP (R1231Q and D1349H) failed to
activate the isolated TKD (Figure S1), signifying that these
are unlikely to be clinically significant. The D1270G-mutated
ALK TKD failed to become autophosphorylated at all, sug-
gesting that this is an inactivating mutation, as expected,
because D1270 lies in the conserved DFG motif essential for
Mg2+-ATP binding to kinases. We did not analyze ALK TKDs
harboring L1204F, L1240V, or I1250T mutations in this
assay because they were poorly expressed as recombinant
proteins.
For more quantitative analyses, we assayed the ability of the
mutated TKDs to phosphorylate a peptide corresponding to
ALK’s activation loop and determined values for kcat, KM, ATP,
and kcat/KM in vitro. We analyzed both fully autophosphorylated
ALK TKDs and nonphosphorylated proteins (phosphatase-
treated as described in the Supplemental Experimental Proce-
dures). The nonphosphorylated ALK TKD represents the ‘‘basal’’
kinase state for each receptor variant, whereas autophosphory-
lated ALK TKDs represent the corresponding activated states
with kcat increased45-fold in the case of wild-type ALK (Bresler
et al., 2011).
Effects of Mutations on the Basal Activity of the
Nonphosphorylated ALK TKD
The effects ofmutations on nonphosphorylated ALK TKD activity
vary according to their location in the kinase. F1174 and F1245
mutations have the strongest effect, increasing the kcat 36- to
39-fold (Figure 3A; Table S4), close to the 45-fold increase
caused by autophosphorylation of the wild-type ALK TKD (Bres-
ler et al., 2011). F1174 and F1245 contribute to a cluster of
phenylalanine side chains (red in Figure 3; the ‘‘Phe core’’) that
normally stabilizes the autoinhibited TKD conformation (Bossi
et al., 2010; Lee et al., 2010). Mutating these residues will desta-
bilize ALK’s autoinhibitory interactions and promote activation.
Almost all of the other significantly activating mutations
(increasing kcat more than 10-fold) occur either at residues in
the aC helix (M1166, I1170, and I1171) or in the short a helix
within the activation loop of the inactive TKD (R1275 and
Y1278). These residues (blue in Figure 3) all participate in autoin-
hibitory interactions between helix aC and the activation loop a
helix that normally stabilize the inactive conformation of the non-686 Cancer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Incphosphorylated ALK TKD (Bossi et al., 2010; Lee et al., 2010) and
are disrupted by the mutations analyzed here. Mutations in the N
lobe (green) or phosphate-binding P loop (cyan) have much
smaller effects on the ALK TKD (Figure 3A). The only exception
is the germline R1192P mutation (which increases the kcat of
nonphosphorylated ALK TKD 15-fold). Mutations in the ALK
TKD active site (magenta) or C lobe (gray) have little or no influ-
ence on the kcat (less than 3-fold increase), except for the
L1196M ‘‘gatekeeper’’ mutation, which increases the kcat nearly
5-fold. Peptide phosphorylation studies further confirmed that
the D1270G variant is inactive (Table S4) and revealed a reduced
activity for the I1250T (SNP) variant, consistent with previous
work (Scho¨nherr et al., 2011a).
KM, ATP values for nonphosphorylated ALK TKD variants (dis-
cussed in more detail below) all fell within a narrow range from
0.13 mM (wild-type) to 0.39 mM (L1196M), suggesting that all
variants are saturated with ATP under physiological conditions
(Figure 3B). Accordingly, catalytic efficiencies (kcat/KM, ATP) for
nonphosphorylated ALK TKD variants (Figure S2A) follow very
similar trends as those seen for the kcat. The same is true for
kcat/KM, peptide values (Figure S2B).
Effects of Neuroblastoma Mutations on the Activity of
the Fully Autophosphorylated ALK TKD
The effects of patient-derived ALK mutations on the activity of
the fully autophosphorylated ALK TKD (prepared as described
in Supplemental Experimental Procedures) were much more
modest. With the exception of the I1170N variant (for which the
kcat was just 35% of that of the wild-type), no variant was altered
more than 2-fold in kcat (Figure 3C; Table S5). Overall, therefore,
neuroblastoma-derived mutations have their greatest effects on
the activity of the nonphosphorylated ALK TKD, promoting its
constitutive autophosphorylation and, thus, ligand-independent
signaling by the intact receptor.
Transforming Ability of Mutated ALK Variants
To assess how biochemical characteristics relate to trans-
forming ability, we measured the ability of intact ALK variants
harboring the same TKD mutations to induce focus formation
in NIH 3T3 cells (Figure 4A). As shown in Figures 4B and 4C,
quantitation of focus formation assays (Table S6) reveals a
remarkably close correspondence between the transforming
potential and in vitro kcat value for the corresponding nonphos-
phorylated TKD variants (Figure 3A). A plot of the transforming.
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No ALK mutation or amplification (n=1,199)
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No ALK mutation or amplification (n=540)
ALK mutation and/or amplification (n=88)
No ALK mutation or amplification (n=540)
ALK mutation and/or amplification (n=88)
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Figure 2. Event-free and Overall Survival
Based on the Presence or Absence of an
ALK Aberration
Shown are Kaplan-Meier curves comparing
patients with and without an ALK aberration
(mutation and/or amplification).
(A) EFS for the entire neuroblastoma cohort,
aberration (n = 149) versus no aberration (n =
1,199), p < 0.0001.
(B) OS for the entire neuroblastoma cohort,
aberration (n = 149) versus no aberration (n =
1,199), p = 0.0002.
(C) EFS for the high-risk cohort, aberration (n = 88)
versus no aberration (n = 540), p = 0.0043.
(D) OS for the high-risk cohort, aberration (n = 88)
versus no aberration (n = 540), p = 0.0018.
See also Table S2.
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yields a straight line with a correlation coefficient (r) of 0.95
(p < 0.0001). Relative outliers were G1128A (in the P loop) and
L1196M (in the active site), which both appeared relatively
more transforming than suggested by in vitro biochemical
data, and M1166R, which appeared less transforming than
expected by this simple correlation. The transforming potential
correlates with the kcat of the nonphosphorylated TKD slightly
better than it does with either measure of catalytic efficiency:
kcat/KM, ATP (r = 0.88) or kcat/KM, peptide (r = 0.89). By contrast,
when transforming ability is plotted against the kcat for phos-
phorylated TKD variants, the slope does not deviate significantly
from zero (p = 0.68), indicating no correlation (Figure 4C;
Figure S2C).
Taken together, the data in Figures 3 and 4 argue that the ac-
tivity of the nonphosphorylated ALK TKD is an excellent predic-
tor of ALK’s transforming ability in NIH 3T3 cells. An increase of
just 4.6- to 4.8-fold in the kcat of the nonphosphorylated ALK TKD
appears sufficient for NIH 3T3 cell transformation, judging from
results with the G1128A (cyan) and L1196M (magenta) variants
(Figure 4; Table S4). The one exception to this correlation is
the N lobe T1151M variant, for which a relatively reduced kcat/
KM, peptide value (Figure S2B; Table S4) may explain the failure
to transform NIH 3T3 cells (presumably because of an elevated
KM, peptide value). It is important to note that none of the three
ALK mutations reported previously in dbSNP (R1231Q, I1250T,
and D1349H; all in the C-lobe) were associated with ALK activa-
tion in transformation or biochemical assays (Figures 3 and 4).
These are silent or passenger mutations. Moreover, an analysis
of the transforming ability in Figure 4B (as a measure of onco-
genicity) paints a very different functional picture from that
predicted by PolyPhen-2 or SIFT across the spectrum of ALK
mutations. These algorithms predict that all mutations (except
R1060H and R1231Q) are damaging or affect function, whereas
our experimental analysis shows that 11 of the 24 mutations
have no significant activating effect. ALK is unlikely to be anCancer Cell 26, 682–694, Nimportant driver in neuroblastoma cases
with any of these nonactivatingmutations,
and crizotinib is therefore very unlikely to
be therapeutically useful in these con-
texts. ‘‘Silent’’ mutations occur in one inapproximately 11 ALK-mutated patients, and it is important to
identify them.
Crizotinib Sensitivities of Recombinant ALK TKD
Variants
At least two of the ALK driver mutations observed in neuro-
blastoma (F1174L and L1196M) have also arisen as acquired cri-
zotinib resistance mutations in tumors driven by oncogenic ALK
fusion proteins (Choi et al., 2010; Sasaki et al., 2010). These find-
ings suggest that primary resistance will be a major concern in
the crizotinib treatment of ALK-mutated neuroblastoma, as we
discussed previously (Bresler et al., 2011). A mere 3-fold
reduction in KM, ATP value appeared sufficient to impair the in vivo
crizotinib sensitivity of F1174L-mutated ALK when compared
with the R1275Q variant, consistent with the appearance of
F1174L as an acquired resistance mutation in both a crizotinib-
treated inflammatory myofibroblastic tumors (Sasaki et al.,
2010) and in vitro screens for crizotinib resistance mutations
in EML4-ALK (Zhang et al., 2011). Table 3 lists KM, ATP values
for the other nonphosphorylated ALK TKD variants described
here. Based solely on reduced KM, ATP values (as for F1174L),
and assuming unchanged crizotinib affinity, the G1128A,
M1166R, F1245C, F1245V, or Y1278S variants would be sug-
gested to be relatively crizotinib-resistant, whereas the I1170N,
I1170S, I1171N, and L1196M (gatekeeper) variants would be
argued to resemble R1275Q in being sensitive to crizotinib
(with relatively larger KM, ATP values). R1192P is intermediate.
Direct measurement of crizotinib half-maximal inhibitory con-
centration (IC50) values in vitro (at 2 mM ATP), however, reveals
that the correlation with KM, ATP values is not simple. The L1196M
(gatekeeper) variant is resistant to crizotinib (Figure S3) despite
its high KM, ATP value, indicating a differential effect of this muta-
tion on ATP and crizotinib binding, as expected from its appear-
ance as an acquired resistancemutation (Katayama et al., 2011).
Similarly, I1171N-mutated ALK is less crizotinib-sensitive in vitro
than a simple view of ATP competition (and KM, ATP values) wouldovember 10, 2014 ª2014 Elsevier Inc. 687
Table 2. Multivariable Analyses Testing the Independence of
Correlations between ALK Mutation Status and EFS
Factors Independently
Statistically Significant
Group with
Increased Risk p Value
Hazard Ratio
(95% CI)
Overall Cohort (n = 1,530a)
INSS stage stage 4 <0.0001 2.9 (2.3, 3.6)
MYCN status amplified <0.0001 1.7 (1.4, 2.1)
11q status aberration <0.0001 1.8 (1.4, 2.4)
Age R18 months <0.0001 1.6 (1.3, 1.9)
Diploidy diploid 0.04 1.2 (1.01, 1.5)
ALK mutation status positive 0.02 1.4 (1.06, 1.9)
Low Risk (n = 620a)
11q status aberration 0.009 2.4 (1.2, 4.7)
Histologic category unfavorable 0.01 2.2 (1.2, 4.1)
Age R18 months 0.02 1.6 (1.3, 1.9)
ALK mutation status positive not
significant
Intermediate Risk (n = 275a)
Histologic category unfavorable 0.03 3.3 (1.1, 9.3)
ALK mutation status positive 0.007 3.1 (1.4, 7.2)
High Risk (n = 546a)
Histologic category unfavorable 0.04 1.8 (1.02, 3.2)
INSS stage stage 4 0.0007 1.8 (1.3, 2.5)
Diploidy diploid 0.01 1.4 (1.1, 1.7)
ALK mutation status positive 0.03 1.5 (1.04, 2.1)
See also Table S3.
aSample size reflects the number of patients with known data for all
factors included in the model.
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emerged alongside F1174 mutations in screens for crizotinib-
resistant variants of EML4-ALK (Zhang et al., 2011). By contrast,
the M1166R, F1245V, and F1245C variants are more sensitive to
crizotinib in vitro than a simple consideration of KM, ATP values
would suggest, resembling the R1275Q variant in our in vitro cri-
zotinib inhibition studies (Table 3) and NIH 3T3 focus assays
(data not shown). This finding is particularly important given
that F1245 is the thirdmost commonlymutated site in neuroblas-
toma, accounting for 12% of mutations. Our data suggest that
cases with F1245 mutations should respond to crizotinib just as
well as R1275Q-mutated tumors.
The data in Table 3 make it clear that the individual ALK
TKD mutations affect binding of ATP and crizotinib in different
ways, and an assessment of IC50 values for a selection of muta-
tions in NIH 3T3 focus assays (data not shown) concurs. For
example, the L1196M mutation impairs crizotinib binding more
than ATP binding, causing resistance to the drug. It will therefore
be important to compare the relative abilities of next-generation
ALK inhibitors to inhibit the variants studied here. One new inhib-
itor, called ceritinib, has been shown recently to inhibit ALK
variants with crizotinib-resistant L1196M or I1171T mutations
(Friboulet et al., 2014) but not to overcome the resistance of an
F1174mutation. Other inhibitors are also known to have differen-
tial effects on crizotinib resistancemutations acquired inALK-re-
arranged lung cancers (Johnson et al., 2014; Sakamoto et al.,688 Cancer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc2011). The data in Table 3 suggest that neuroblastoma patients
with ALK-activating M1166R, I1170N/S, or F1245 mutations
should respond to crizotinib just as well as R1275Q-mutated pa-
tients. Patients with I1171 or L1196 mutations are likely to
respond better to ceritinib, and those with F1174L (and possible
other) mutations might be more responsive to the macrocyclic
inhibitor PF-06463922 (Johnson et al., 2014). Y1278, R1192,
and G1128 mutations appear to be intermediate between these
two groups, and comparative studies of ALK inhibitors are
needed to determine which inhibitor would be best for these
cases.
Computational Analysis of Mutated ALK TKDs
The poor performance of existing informatics-based approaches
in distinguishing activating from nonactivating amino acid substi-
tutions prompted us to investigate structure-based computa-
tional methods for assessing newly emerging ALK mutations.
Importantly, apart from data published already, the computa-
tional analysis was done without prior knowledge of biochemical
results emerging from this study. As described in the Supple-
mental Experimental Procedures, we simulated molecular dy-
namics (MD) trajectories for the inactive conformation of all
mutated ALK TKD variants and for the wild-type ALK TKD in
both active and inactive conformations. The resulting MD trajec-
tories were analyzed for three key structural properties:
hydrogen-bonding networks, hydrophobic interaction networks,
and principal component analysis.
Hydrogen-Bonding Network
Distinct sets of key intramolecular hydrogen bonds characterize
the active and inactive ALK TKD configurations. Those that
maintain the (autoinhibited) positions of the activation loop and
aC helix in the inactive TKD (Figure 3D) are absent in the active
structure. A simple scoring function (Supplemental Experimental
Procedures) was used to determine whether each mutation pro-
motes a more ‘‘active-like’’ or ‘‘inactive-like’’ hydrogen-bonding
network (Table 4).
Hydrophobic Interaction Network
As mentioned above, key autoinhibitory interactions are stabi-
lized in the inactive conformation by residues with hydrophobic
side chains, notably those in the Phe core (red in Figure 3D)
and contacts between the aC helix and short activation loop he-
lix (blue in Figure 3D). Disruption of these autoinhibitory
hydrophobic interactions can be assessed readily by monitoring
the solvent-accessible surface area (SASA) of relevant residues
throughout the MD trajectories. If the SASA increases as a result
of a neuroblastoma mutation, the mutation is classed as ‘‘acti-
vating.’’ To further determine whether observed changes in
SASA favor the active state, free energy perturbation (FEP) sim-
ulations were used to determine whether each mutation signifi-
cantly destabilizes the inactive state relative to the active state
(in which case it is classed as activating).
Principal Component Analysis
A principal component analysis (PCA) reveals correlated
global motions across the MD trajectory. The top ten domi-
nant modes are considerably different (greater) in the active
conformation than in the inactive ALK TKD (indicating greater
motion), as seen for other kinases (Shih et al., 2011). As out-
lined in the Supplemental Experimental Procedures, each mu-
tation with a top eigenvalue above 200 A˚2 is scored as.
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Figure 3. kcat and KM, ATP Values for Mutated ALK TKD Variants
(A) kcat values determined for nonphosphorylated ALK TKD variants at saturating (2 mM) ATP, with 2 mM YYY peptide and 10 mM MgCl2.
(B) KM, ATP values for nonphosphorylated ALK TKD variants, determined with YYY peptide at 1.0 mM, ATP concentrations from 0.3125–2.0 mM, and MgCl2 at
10 mM. Data for wild-type, F1174L, and R1275Q variants have been reported previously (Bresler et al., 2011).
(C) kcat values for phosphorylated ALK TKD variants, determined as in (A). Data (obtained at 25
C) are shown as mean ± SEM from at least three independent
experiments.
(D) ALK TKD crystal structure from Protein Data Bank ID code 3LCS (Lee et al., 2010) with important structural regions colored as follows: aC/activation loop
interface, blue; Phe core, red; P loop, cyan; N lobe, green; active site, magenta; and C lobe, gray.
See also Figure S2 and Tables S4 and S5.
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ALK-Based Stratification of Neuroblastoma Patientsactivating (indicating destabilization of key autoinhibitory
interactions).
A mutation is predicted to be activating overall if it scores as
such in one ormore of the three criteria outlined above. As shown
in Table 4, predictions for eachmutated ALK TKD variant studied
here agree quite well with our experimental studies. Moreover,
the computational analysis suggests a possible mechanism of
activation for each mutation, i.e., by perturbing hydrophilic inter-
actions, hydrophobic interactions, or global conformation. All of
themutations that elevate the kcat of the nonphosphorylated ALK
TKD more than 5-fold were predicted correctly, except two
(I1171N and F1245C), as listed in Table 4. Perhaps more impor-
tantly, our computational analysis correctly predicts the majority
of mutations that are not activating, therefore showing its value in
distinguishing passenger from driver mutations and its potential
utility for patient stratification. There are a few exceptions, how-
ever. The T1151M mutation was designated as activating in our
computational analysis, but did not transform NIH 3T3 cells (Fig-
ure 4). Although a biochemical analysis indicated an elevated kcat
for this variant, it has a reduced kcat/KM, peptide value, apparently
arising from an elevated KM, peptide value that would not be
captured computationally. The I1250T and D1270G mutations,
both also predicted to be activating using our computationalCanapproach, are special cases. D1270 is the conserved DFG
aspartate, and loss of its side chain removes a functional group
essential for Mg2+ binding to the TKD. The I1250T mutation
impairs protein stability and/or folding (as assessed by poor
expression) in a way that the model cannot predict, so no acti-
vating effect is seen experimentally. The computational analysis
also failed to predict three transforming mutations (Table 4),
F1245C, I1171N, and L1196M (the gatekeepermutation), for rea-
sons that are less clear. Overall, however, our computational
approach correctly predicts 75% of the transforming mutations
and, importantly, over 75%of silent mutations (excepting special
cases). By contrast, PolyPhen-2 (Table 4, rightmost column) pre-
dicts only one silent mutation correctly and is plagued with false
positives. It is important to reiterate that our computational
studies were undertaken with no prior knowledge of the results
shown in Figures 3 and 4 (with the exception of those published
previously).
DISCUSSION
The discovery of activating mutations in the intact ALK gene as
drivers in neuroblastoma provided the first example of a pediat-
ric cancer caused by germline mutations in an oncogene andcer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc. 689
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Figure 4. Transformation Potential of ALK
Mutations from NIH 3T3 Focus Formation
Assays
(A) Representative focus formation assays for NIH
3T3 cells transfected with intact ALK variants or
empty vector.
(B) Quantitation of data from (A). To correct for
transfection efficiency, the number of foci for each
transfection was divided by the number of G418-
resistant colonies, and the transforming ability was
plotted as foci per G418-resistant colony. Each
independent experiment was performed in dupli-
cate, and data are presented as mean ± SEM of at
least three independent experiments (Table S6).
(C) Plots of the ALK transforming ability against
the in vitro kcat for nonphosphorylated ALK TKD
(left) or autophosphorylated ALK TKD (right). The
lines are linear regressions to the data. Correlation
coefficients were 0.95 (nonphosphorylated) and
0.095 (phosphorylated), with a significant deviation
from zero for the nonphosphorylated ALK TKD
(p < 0.0001) but not for the phosphorylated ALK
TKD (p = 0.68).
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ALK-Based Stratification of Neuroblastoma Patientsthe only druggable mutation in a pediatric solid tumor. We char-
acterized the spectrum and frequency of germline and somatic
alterations in ALK across all neuroblastoma disease subsets
in 1,596 patients. This data set is powered to identify ALK mu-
tations in neuroblastoma that, although rare, are still clinically
relevant and to have sufficient power to determine the prog-
nostic capability of ALK alterations within each neuroblastoma
risk group (high, intermediate, and low). In addition, cataloguing
ALK mutations in these tumors allowed us to correlate
sequence variations with oncogenic potency. Some of the
observed mutations are unlikely to be oncogenic, and the acti-690 Cancer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc.vated variants differ in their sensitivity to
crizotinib, with potentially important ther-
apeutic implications. In multivariable
models of the overall cohort, and within
each risk group, both the presence of
an ALK mutation (except within the low-
risk group) and the presence of any ALK
aberration were shown to correlate inde-
pendently with worse EFS. These find-
ings illustrate the value of determining
the ALK status for prognostic patient
stratification and also support the poten-
tial importance of ALK as a therapeutic
target.
ALK mutations are observed in 8% of
neuroblastoma patients and span the
entire spectrum of disease, including In-
ternational Neuroblastoma Staging Sys-
tem (INSS) stage 4 disease, congenital
cases, and adolescents/young adults.
The fact that ALK mutations occur at the
highest frequency (17%) in patients older
than 10 suggests differences in the occur-
rence of genetic mutations based on age,
reminiscent of the recently reported agedistribution of ATRX mutations in neuroblastoma (Cheung
et al., 2012). Within the high-risk subset of neuroblastoma pa-
tients, the overall frequency of ALK aberration is 14% (10% mu-
tation, 4% amplification). High-risk patients have the poorest
outcomes, with approximately only 50% OS despite intensive
multimodal therapy, including chemotherapy, surgery, myeloa-
blative conditioning with bone marrow transplant, radiation ther-
apy, and immunotherapy plus retinoic acid (Maris, 2010), mak-
ing these patients excellent candidates for ALK-targeted
therapy. Within the low- and intermediate-risk groups, the
frequency of ALK aberration is 6% and 8%, respectively. In
Table 3. Crizotinib Sensitivities of Nonphosphorylated ALK-TKD
Mutants at 2.0 mM ATP
ALK TKD
Variant KM, ATP (mM)
a
Crizotinib
IC50 (nM)
at 2 mM ATPa
Predicted Crizotinib
Sensitivity
from KM, ATP from IC50
G1128A 0.152 ± 0.008 138 ± 21 – –
M1166R 0.149 ± 0.004 76.1 ± 2.4 – +
I1170N 0.297 ± 0.015 77.5 ± 3.5 + +
I1170S 0.371 ± 0.013 76.4 ± 7.7 + +
I1171N 0.250 ± 0.013 157 ± 11 + –
F1174Lb 0.127 ± 0.011 130 ± 10 – –
R1192P 0.192 ± 0.007 90.5 ± 4.7 –/+ –/+
L1196M 0.387 ± 0.033 521 ± 4 + –
F1245C 0.138 ± 0.001 79.2 ± 7.5 – +
F1245V 0.152 ± 0.009 86.9 ± 2.0 – +
R1275Qb 0.326 ± 0.033 84.6 ± 8.0 + +
Y1278S 0.152 ± 0.012 113 ± 5 – –
Crizotinib concentration was varied from 0–25,600 nM with ATP at
2.0 mM, YYY peptide at 0.5 mM, and enzyme held fixed at 50 nM. See
also Figure S3.
aResults are reported as mean ± SEM of at least three independent
experiments.
bValues determined and reported previously (Bresler et al., 2011).
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without surgical intervention, whereas patients with intermedi-
ate-risk disease are treated with conventional cytotoxic chemo-
therapy and are at risk for the associated late effects. Our results
suggest an important opportunity within the intermediate-risk
group to identify those with an activating ALKmutation for treat-
ment with ALK inhibitors and de-escalation of traditional cyto-
toxic therapy.
Of the 24 different patient-derived ALK mutations assessed,
only 13 drove transformation of NIH 3T3 cells. Where our studies
overlap with other analyses of transformation by ALK variants
found in neuroblastoma, they are in complete agreement (Chand
et al., 2013; George et al., 2008; Scho¨nherr et al., 2011a, 2011b).
Importantly, every mutation that promoted transformation also
constitutively activated the ALK TKD, with remarkable correla-
tion between the transforming activity and in vitro kcat value for
the nonphosphorylated TKD. Eleven of the 24 mutations (repre-
senting 9% of ALK-mutated patients in this study) appeared
silent or even inactivating. Of the activatingmutations, in vitro an-
alyses suggest that only six (including R1275Q) will be sensitive
to inhibition by crizotinib in vivo. Some others are likely to
respond better to next-generation inhibitors that appear capable
of inhibiting L1196M and I1171 variants (ceritinib) or F1174
variants (PF-06463922). Further comparative studies with these
inhibitors are required to identify which one is optimal for each
variant.
Using anMD-based computational approach, we showed that
we can predict which mutations are activating and, more impor-
tantly, which are not activating, with a success rate that greatly
exceeds methods such as SIFT, PolyPhen-2, PredictSNP, and
others. For example, our method correctly (and blindly) pre-
dicted the consequences of all ALK mutations uncovered in
this report, with D1270G as the one exception (where a catalyt-Canically crucial residue is mutated). It is important to note that
our computational analysis assesses kinase activation and not
transformation itself, but our biochemical data indicate that
elevating the kcat of the nonphosphorylated ALK TKD 4.6-fold
or more causes the receptor to be transforming. Our computa-
tional analysis ofALKmutations has significant promise as a clin-
ical tool and will improve with further training and testing using
additional clinically observed (and experimental) mutations. It
will also be important to apply computational approaches similar
to those that we have employed for the epidermal growth factor
receptor (EGFR) (Park et al., 2012) in efforts to predict inhibitor
sensitivity.
Our findings allow us to formulate molecular diagnostic
screening recommendations for newly diagnosed neuroblas-
toma patients that will be important in the clinical evaluation
of ALK inhibitors for childhood cancer. We demonstrate that
ALK is a predictive therapeutic biomarker of disease status
and that it also provides a therapeutic target in a select group
of patients. With additional molecularly targeted therapeutics
and computational models that leverage biochemical under-
standing to predict the effect of newly emerging ALKmutations,
we should now be able to make up-front predictions about
which patients are most likely to respond to crizotinib or other
ALK inhibitors and (importantly) identify those that will not.
Related approaches have been successful with imatinib in
chronic myeloid leukemia, gefitinib in NSCLC, and, most
recently, crizotinib in ALK-translocated NSCLC, although func-
tional stratification of individual mutations along the lines
described here has not yet been achieved. We are now poised
to develop a responder hypothesis as part of a therapeutic
strategy that incorporates pharmacologic ALK inhibition into
the backbone of contemporary treatment regimens in neuro-
blastoma. Our phase 1 trial of crizotinib showed some prom-
ising responses even in heavily pretreated patients with ALK
mutations with recurrent or refractory late-stage disease (Mosse´
et al., 2013), despite the fact that these heavily pretreated pa-
tients are frequently multidrug resistant and also show an
increased prevalence of p53 mutations at relapse (Carr-Wilkin-
son et al., 2010), confounding factors that were not assessed.
In newly diagnosed patients, where these issues are not rele-
vant (and p53 mutations are rare), we expect up-front ALK-tar-
geted treatment guided by the results described here to yield
dramatically improved results.
In addition, our findings will help advance the management of
individuals with neuroblastoma predisposition. Individuals with
a germline ALK variation of unknown significance may have
siblings who also harbor these variants, emphasizing the
importance of understanding which alleles are risk alleles to
determine their risk of developing neuroblastoma and to offer
appropriate clinical screening. No models have yet been estab-
lished for effective early detection strategies or improving clin-
ical outcomes when germline ALK variations are detected.
Implementing clinical surveillance strategies for unaffected chil-
dren (possibly even adults) with neuroblastoma carrying a
germline ALK variant should be guided by data such as those
presented here, recognizing the implications of the use of pre-
dictive genetic screening and surveillance practices and the
absence of evidence of benefit from early detection in these
individuals.cer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Inc. 691
Table 4. Computational Prediction of Effects of ALK TKD Mutations
Variant kcat (min
1)a
Activated
In Vitro?b
Changes Indicative of Kinase
Activation in MD Simulations of Overall Prediction
of Activation In Silico?
Transforming
in NIH 3T3?c
PolyPhen-2 Prediction
(Probability)dH-Bonds SASA/FEP PCA
F1174L 365 C C – C C C C (0.70)
F1245V 341 C C – – C C C (1.00)
F1245C 329 C – – – – C C (1.00)
I1170N 200 C C C – C C C (1.00)
I1170S 200 C – C – C C C (1.00)
I1171N 188 C – – – – C C (1.00)
Y1278S 172 C – – C C C C (0.99)
R1192P 139 C C – C C C C (0.99)
M1166R 127 C C – – C B C (0.99)
R1275Q 119 C C – – C C C (1.00)
T1151M 53 C C – – C – C (0.98)
L1196M 45 C – – – – B C (1.00)
G1128A 43 C C – – C B C (1.00)
I1183T 32 – – – – – – C (0.96)
L1204F 28 – – – – – – C (0.99)
G1286R 16 – – – – – – C (0.98)
A1200V 11 – – – – – – C (0.67)
D1349H 11 – – – – – – C (0.94)
Wild-type 9 – NA NA NA NA – NA
T1343I 9 – – – – – – C (0.84)
R1231Q 5 – – – – – – - (0.01)
I1250Te 3 – – C – Ce – Ce(1.00)
D1270Ge 1 – C – – Ce – Ce(1.00)
aThe kcat for nonphosphorylated TKD is listed from Table S4.
bA variant is considered activated in vitro if the kcat for nonphosphorylated TKD exceeds 4.6 times that of the wild-type (see text).
cOpen circles represent weak transformation (see Figure 4).
dFilled black circles in the PolyPhen-2 column indicate that this algorithm predicts that themutation is damaging. The probabilities in parentheses were
taken from the PolyPhen-2 batch run at http://genetics.bwh.harvard.edu/pph2/ (Adzhubei et al., 2010).
eThe D1270G and I1250T mutations are known to be inactivating (this work and Scho¨nherr et al., 2011a). D1270G disrupts the DFG motif, and I1250T
expresses poorly, suggesting compromised folding.
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Patient Population
The ALK genomic status was evaluated in 1,596 diagnostic tumor DNA
samples from patients enrolled on COG neuroblastoma biology protocol
ANBL00B1. Matched germline DNA was available in 88 of the 126 cases
with identified ALK mutations. Most samples were annotated with clinical
and genomic information including age, site of origin, INSS stage, International
Neuroblastoma Pathologic Classification (INPC),MYCN copy number, DNA in-
dex, registration on clinical trial(s), event-free and overall survival, and tumor
DNA copy number/loss of heterozygosity (LOH) status at chromosome bands
1p36 and 11q23 (Attiyeh et al., 2005; Morowitz et al., 2003). All cases had a
confirmed diagnosis of neuroblastoma and had associated informed consent
and enrollment in a COG biology study. This research was approved by the
Children’s Hospital of Philadelphia Institutional Review Board and the Cancer
Therapy Evaluation Program.
Sequencing and Copy Number Determination
Sanger-based DNA resequencing of the ALK TKD (exons 21–28) was per-
formed by Beckman Coulter Genomics using BigDye Terminator v3.1 cycle
sequencing chemistry on an ABI PRISM 3730xl sequencer. Electrophero-
grams were analyzed using Sequencher 4.9 software. For each tumor
harboring a somatic mutation, we sequenced the corresponding amplicon692 Cancer Cell 26, 682–694, November 10, 2014 ª2014 Elsevier Incin matched germline DNA where available. Variations were cross-checked
for polymorphism status in the dbSNP and COSMIC databases and a
panel of 218 normal control alleles. Copy number determination employed
whole-genome SNP array analyses (550,000) for 577 samples and real-
time quantitative PCR for 1,122 samples (Supplemental Experimental
Procedures).
Statistical Considerations
Risk factors tested for prognostic significance were age (<18 months
versus R18 months), INSS stage (stage 1,2,3,4 s versus stage 4), histology
(favorable versus unfavorable), ploidy (hyperdiploid versus diploid),MYCN sta-
tus (not amplified versus amplified), 11q status (no loss versus LOH), and 1p
status (no loss versus LOH). For univariable analyses, EFS and OS times
were calculated as described in the Supplemental Experimental Procedures.
A chi-square test was used to test the association between each risk factor
and the presence of an ALKmutation, the presence of ALK copy number vari-
ation, and the presence of any ALK aberration. The p values were not adjusted
for multiple comparisons, with p < 0.05 considered statistically significant.
For multivariable analyses, using backward selection model building, a Cox
proportional hazards regression model was used to test for the independent
statistical significance of ALK mutations or copy number variations after
adjustment for statistically significant risk factors and to calculate the p value
and HR for each factor..
Cancer Cell
ALK-Based Stratification of Neuroblastoma PatientsRecombinant Protein Expression, Purification, and Analysis
Histidine-tagged wild-type and mutated ALK TKD variants were produced
from baculovirus-infected Sf9 cells in nonphosphorylated and fully autophos-
phorylated forms, as described previously (Bresler et al., 2011), and assessed
for kinase activity as described in the Supplemental Experimental Procedures.
Focus Formation Assays
Focus formation assays were performed as described previously (Burke et al.,
1997), with details shown in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.09.019.
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